Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Statistics
Share Statistics
Lexaria Bioscience has 17.55M shares outstanding. The number of shares has increased by 41% in one year.
| Shares Outstanding | 17.55M |
| Shares Change (YoY) | 41% |
| Shares Change (QoQ) | 10.39% |
| Owned by Institutions (%) | 7.66% |
| Shares Floating | 16.27M |
| Failed to Deliver (FTD) Shares | 6.86K |
| FTD / Avg. Volume | 3.87% |
Short Selling Information
The latest short interest is 342.37K, so 1.95% of the outstanding shares have been sold short.
| Short Interest | 342.37K |
| Short % of Shares Out | 1.95% |
| Short % of Float | 2.11% |
| Short Ratio (days to cover) | 2.34 |
Valuation Ratios
The PE ratio is -8.36 and the forward PE ratio is -4.38. Lexaria Bioscience's PEG ratio is 0.16.
| PE Ratio | -8.36 |
| Forward PE | -4.38 |
| PS Ratio | 104.29 |
| Forward PS | 0.5 |
| PB Ratio | 6.03 |
| P/FCF Ratio | -9.76 |
| PEG Ratio | 0.16 |
Enterprise Valuation
Lexaria Bioscience Corp. has an Enterprise Value (EV) of 5.76M.
| EV / Earnings | -0.99 |
| EV / Sales | 12.4 |
| EV / EBITDA | -1.01 |
| EV / EBIT | -1 |
| EV / FCF | -1.16 |
Financial Position
The company has a current ratio of 7.18, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.18 |
| Quick Ratio | 7.18 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.68 |
| Cash Flow / Debt | -36.1 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.72% and return on capital (ROIC) is -73.79%.
| Return on Equity (ROE) | -0.72% |
| Return on Assets (ROA) | -0.65% |
| Return on Capital (ROIC) | -73.79% |
| Revenue Per Employee | $66,325.43 |
| Profits Per Employee | $-827,906.43 |
| Employee Count | 7 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -56.33% in the last 52 weeks. The beta is 0.96, so Lexaria Bioscience's price volatility has been higher than the market average.
| Beta | 0.96 |
| 52-Week Price Change | -56.33% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 31.2 |
| Average Volume (20 Days) | 177.54K |
Income Statement
In the last 12 months, Lexaria Bioscience had revenue of 464.28K and earned -5.8M in profits. Earnings per share was -0.47.
| Revenue | 464.28K |
| Gross Profit | 459.46K |
| Operating Income | -5.75M |
| Net Income | -5.8M |
| EBITDA | -5.68M |
| EBIT | -5.75M |
| Earnings Per Share (EPS) | -0.47 |
Balance Sheet
The company has 6.5M in cash and 137.37K in debt, giving a net cash position of 6.36M.
| Cash & Cash Equivalents | 6.5M |
| Total Debt | 137.37K |
| Net Cash | 6.36M |
| Retained Earnings | -51.56M |
| Total Assets | 9.79M |
| Working Capital | 8.53M |
Cash Flow
In the last 12 months, operating cash flow was -4.96M and capital expenditures -43.01K, giving a free cash flow of -4.96M.
| Operating Cash Flow | -4.96M |
| Capital Expenditures | -43.01K |
| Free Cash Flow | -4.96M |
| FCF Per Share | -0.4 |
Margins
Gross margin is 98.96%, with operating and profit margins of -1.24K% and -1.25K%.
| Gross Margin | 98.96% |
| Operating Margin | -1.24K% |
| Pretax Margin | -1.25K% |
| Profit Margin | -1.25K% |
| EBITDA Margin | -1.22K% |
| EBIT Margin | -1.24K% |
| FCF Margin | -1.07K% |
Dividends & Yields
LEXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.88% |
| FCF Yield | -21.51% |
Analyst Forecast
The average price target for LEXX is $9.5, which is 625.2% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.5 |
| Price Target Difference | 625.2% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 12, 2021. It was a backward split with a ratio of 1:30.
| Last Split Date | Jan 12, 2021 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | 31.2 |
| Piotroski F-Score | 3 |